190 related articles for article (PubMed ID: 11205197)
1. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
[TBL] [Abstract][Full Text] [Related]
2. Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
Lee JK; Tsai SC; Hsieh JF; Ho YJ; Sun SS; Kao CH
Anticancer Res; 2000; 20(6C):4765-8. PubMed ID: 11205215
[TBL] [Abstract][Full Text] [Related]
3. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
4. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
Lin WY; Yen TC; Cheng KY; Wang SJ
Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
[TBL] [Abstract][Full Text] [Related]
5. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
[TBL] [Abstract][Full Text] [Related]
7. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.
Wei YS; Zheng YH; Liang WB; Zhang JZ; Yang ZH; Lv ML; Jia J; Zhang L
Cancer; 2008 Feb; 112(3):544-51. PubMed ID: 18085639
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM
Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026
[TBL] [Abstract][Full Text] [Related]
9. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
[TBL] [Abstract][Full Text] [Related]
10. Serum tissue polypeptide specific antigen (TPS) in patients with cervical carcinoma: preliminary report.
Pattaranutaporn P; Chansilpa Y; Tangkarat S; Tepmongkol P; Sangruchi S; Senapad S
Anticancer Res; 1997; 17(3C):2309-12. PubMed ID: 9216707
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
12. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Fröhlich B; Bieglmayr C; Tatra G
Anticancer Res; 1992; 12(4):1247-9. PubMed ID: 1503417
[TBL] [Abstract][Full Text] [Related]
13. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis.
Chang KP; Wu CC; Chen HC; Chen SJ; Peng PH; Tsang NM; Lee LY; Liu SC; Liang Y; Lee YS; Hao SP; Chang YS; Yu JS
Proteomics; 2010 Jul; 10(14):2644-60. PubMed ID: 20461718
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
[TBL] [Abstract][Full Text] [Related]
15. [The value of marker antigens TPS, SCC and CEA in diagnosis, evaluation of histologic type and clinical disease progression in patients with cervical carcinoma].
Zakrzewska I
Pol Merkur Lekarski; 2001 Jan; 10(55):21-3. PubMed ID: 11320545
[TBL] [Abstract][Full Text] [Related]
16. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
19. Serum tissue polypeptide specific antigen (TPS) in locoregional failure and distant metastasis of cervical carcinoma.
Pattaranutaporn P; Chansilpa Y; Ieumwananonthachai N; Sukkasem M
J Med Assoc Thai; 2000 Sep; 83(9):1011-5. PubMed ID: 11075966
[TBL] [Abstract][Full Text] [Related]
20. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
